Valley wants our patients and community to be on the alert against medical billing scams. Learn how to protect yourself and your personal information from scammers posing as hospital representatives.
Read MoreA Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Objective
This randomized Phase 2 open-label study will evaluate the safety and efficacy of Zimberelimab (AB122) monotherapy, AB154 in combination with Zimberelimab, and AB154 in combination with Zimberelimab and AB928 in front-line, PD-L1 positive, locally advanced or metastatic non-small cell lung cancer.
Study Arms
- Experimental: Arm 1 (Zimberelimab Monotherapy)
- Experimental: Arm 2 (AB154 and Zimberelimab Combination Therapy
- Experimental: Arm 3 (AB154, Zimberelimab, and AB928 Combination Therapy)
Eligibility
- Male or female participants; age ≥ 18 years
- Histologically confirmed squamous or nonsquamous, PD-L1 positive, NSCLC that is locally advanced or metastatic without sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation expression
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Must have at least 1 measurable lesion per RECIST v1.1
- Adequate organ and marrow function
NCT ID
NCT04262856